Obesity is rising and in the last 35 years, has more than doubled. The world population in 1999 to today is 42% or 22 million adults with a body mass index of 40 or higher.

Bad news for Eli Lilly (LLY -7.38%) stock dragged down shares of rival companies in the market for GLP-1 diet drugs on Tuesday. Lilly updated investors on its expected revenue for 2024 this morning, a...

Novo Nordisk (NYSE:NVO) fourth-quarter results on February 5, 2025, will be a big announcement for Europe's largest company given the febrile excitement surrounding its blockbuster appetite-reducing /...

In the most recent trading session, Novo Nordisk (NVO) closed at $84.62, indicating a -1.9% shift from the previous trading day.

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

I aim to create a $500,000 portfolio for passive income, focusing on high-yield and growth companies to outpace inflation. My portfolio includes 10 companies: 70% stable high-yielders like Pepsi, BTI,...

You will want to build your portfolio the right way if you're going to make money with stocks over the long haul. You wouldn't build your house on a shaky foundation, would you?

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.

Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand recognition of Ozempic and Wegovy.

Novo Nordisk's (NVO) U.S.-listed and domestic shares rose Wednesday after analysts from UBS Research upgraded the Danish drugmaker's stock to "buy" from "neutral," calling the recent sell-off of the s...

Putting tariffs on Denmark unless it cedes the island of Greenland could hurt access to a few key products, including popular medicines.

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using human data and arti...

On Wednesday, Novo Nordisk A/S NVO and Valo Health, Inc. entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease.

Eli Lilly (LLY -0.27%) and Novo Nordisk (NVO 2.04%) are two of the most valuable healthcare stocks in the world, largely due to their successful diabetes and weight loss medications. They are also big...

U.S.-listed shares of Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) are up 3.5% premarket, following a bull note from UBS.

At least four analysts weighed in on the prospects for Europe's second-largest company, Novo Nordisk, after the Danish drugmaker reported disappointing results for its next-generation weight-loss drug...

Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental obesity pill, and supply capacity for Ozempic and Wegovy.

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $83.34, denoting a -1.99% change from the preceding trading day.

It's not at all clear what a tariff would mean for Novo, which manufactures its medicines in facilities all over the world, including in the U.S.